Computer aided therapeutic tripeptide design, in alleviating the pathogenic proclivities of nocuous α-synuclein fibrils
Authors:
- 24 March 2023
- journal article
- research article
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (1) , 483-494
Abstract
Parkinson’s disorder (PD) exacerbates neuronal degeneration of motor nerves, thereby effectuating uncoordinated movements and tremors. Aberrant alpha-synuclein (α-syn) is culpable of triggering PD, wherein cytotoxic amyloid aggregates of α-syn get deposited in motor neurons to instigate neuro-degeneration. Amyloid aggregates, typically rich in beta sheets are cardinal targets to mitigate their neurotoxic effects. In this analysis, owing to their interaction specificity, we formulated an efficacious tripeptide out of the aggregation-prone region of α-syn protein. With the help of a proficient computational pipeline, systematic peptide shortening and an adept molecular simulation platform, we formulated a tripeptide, VAV from α-syn structure based hexapeptide KISVRV. Indeed, the VAV tripeptide was able to effectively mitigate the α-syn amyloid fibrils’ dynamic rate of beta-sheet formation. Additional trajectory analyses of the VAV- α-syn complex indicated that, upon its dynamic interaction, VAV efficiently altered the distinct pathogenic structural dynamics of α-syn, further advocating its potential in alleviating aberrant α-syn’s amyloidogenic proclivities. Consistent findings from various computational analyses have led us to surmise that VAV could potentially re-alter the pathogenic conformational orientation of α-syn, essential to mitigate its cytotoxicity. Hence, VAV tripeptide could be an efficacious therapeutic candidate to efficiently ameliorate aberrant α-syn amyloid mediated neurotoxicity, eventually attenuating the nocuous effects of PD. Communicated by Ramaswamy H. SarmaKeywords
Funding Information
- Indian Council of Medical Research
This publication has 85 references indexed in Scilit:
- Contribution of isoprene-derived organosulfates to free tropospheric aerosol massProceedings of the National Academy of Sciences, 2010
- Structural characterization of α‐synuclein in an aggregation prone stateProtein Science, 2009
- Role of Synucleins in Alzheimer’s DiseaseNeurotoxicity Research, 2009
- Ab Initio Folding of Proteins with All-Atom Discrete Molecular DynamicsStructure, 2008
- The fold of α-synuclein fibrilsProceedings of the National Academy of Sciences, 2008
- α‐Synuclein produces a long‐lasting increase in neurotransmitter releaseThe EMBO Journal, 2004
- Protein folding and misfoldingNature, 2003
- Alpha-synuclein and neurodegenerative diseasesNature Reviews Neuroscience, 2001
- Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformationProceedings of the National Academy of Sciences, 2000
- α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodiesProceedings of the National Academy of Sciences, 1998